Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapies for Down Syndrome Regression Disorder
NCT05662228Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Jun 2023
- Primary completion
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lorazepam, intravenous immunoglobulin G, tofacitinib oral solution in Down syndrome regression disorder (DSRD), sponsored by University of Colorado Denver. Started Jun 2023; status: completed.
02
Drugs
lorazepamintravenous immunoglobulin Gtofacitinib oral solution
03
Conditions
Down syndrome regression disorder (DSRD)
Beyond the preview
Go deeper on NCT05662228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662228.